Suzhou Biopharmaceutical Special Mother Fund Announcement: Plans to Invest in and Deploy "AI + Biotechnology"
Recently,Suzhou Biopharmaceutical Industry Special Parent FundPublish the latest selection results announcement, planning to contribute funds to establish "Shenwan Gongrong Zhiyi Strategic Emerging Equity Investment Fund Partnership (Limited Partnership)”。
△ Source: Suzhou Bio-pharmaceutical Industry Special Parent Fund Public Announcement
The investment focus of this sub-fund is clearly defined—centered on"AI + Biotechnology"Focus on emerging industries, prioritizing AI+Biotech, AI+Pharma, AI+Healthcare, synthetic biology, and life sciences. Prioritize upstream general technology platform projects, as well as growth-stage and mature projects with significant core technological competitiveness.
A fund size of 5 billion isn't large, but its signal value far exceeds the number itself. This is the first "AI + Biotech" themed sub-fund invested in by Suzhou's special biopharmaceutical parent fund—a landmark case where a local industrial parent fund systematically enters AI drug discovery through targeted co-investment.
Local funds and central SOEs are ramping up investments in AI-driven drug discovery.
Suzhou is not the only player making moves in AI-driven drug discovery.
In 6 of this year,Xiaogan High-Tech Industry Investment Co., Ltd.Launch a selection announcement and establish a Bio-Tech Angel Investment Fund. The fund focuses on AI-driven drug discovery, computing power-enabled pharmaceuticals, and bio-manufacturing, with primary investments in angel and Pre-A rounds.
Xiaogan's ace isYangtze 3D Scientific Computing CenterPossesses nationwide scarcity in computing power services for the biopharmaceutical sector. "Computing Power + Biopharma" is the region's core industrial development strategy; when selecting GPs, a combined expertise in both computing and pharmaceuticals is explicitly prioritized.
The SOE moves are even more significant. Under the Guoxin Fund system,Central SOE Strategic Emerging Industries Fund，Initial scale of 510 billion yuan, with a focus on next-generation information technology, artificial intelligence, biomedicine, and other key areas. In 6 this year, Guoxin Venture Capital led the investment inBaiyao TechnologyPre-A round. This represents Guoxin Fund's early exploratory investment in the AI drug discovery sector. Baiyao Technology was founded in 2024 11, specializing in AI virtual cell technology. The founding team hails from the Institute of Zoology, Chinese Academy of Sciences, and the Beijing Institute for Stem Cell and Regenerative Medicine. They began building the foundational large model for AI virtual cells as early as 2023.
From local firms to central SOEs, from angel investors to strategic emerging industry funds, state capital is systematically entering AI drug investment—not as scattered experiments, but as a coordinated rollout.
How hot is the funding for AI-driven drug discovery?
The data speaks volumes.
In the first half of 2026, AI drug discovery funding remained robust. Domestically, industry reviews indicate that at least 13 AI pharmaceutical companies secured new rounds of financing during this period.Total financing exceeds 10 billion yuanGlobally, AI drug discovery companies secured approximately $0 billion in funding in Q1 alone. This is no longer small-scale experimentation in the conceptual phase.
See a few more representative cases.
Dewei PharmaceuticalCompleted $20 million Series B funding in 7 month 8. The core pipeline MDR-001 is China's first AI-driven drug to advance to Phase III. This oral small-molecule GLP-1RA reached Phase III just 4.5 years after project initiation, with cumulative investment of approximately $60,000.
Pharmaceutical RanchSecured $2 million in Series D funding on 7/13, led by Shanghai Pudong Leading Zone Investment. Pipeline candidate DF-003 is a first-in-class (FIC) drug targeting AI + genetics and has entered Phase III clinical trials.
Molecular MindCompleted a $200M+ Series A round in 6 month 17 day, with participation from Blue Bridge Capital, Fosun Capital, Pudong Venture Capital, and others. Focus: AI-driven protein design.
Jitai TechnologyIn 5 this year, the Hong Kong IPO opened above its issue price on day one, surging over 170%. 18 cornerstone investors subscribed to 1.48 billion USD. The central state-owned enterprise's strategic emerging fund invested in AI drug discovery as a cornerstone investor. The national team backed AI drug development with real capital.
Two more signals to watch. First, CSPC Pharmaceutical Group and AstraZeneca have reached 4 AI collaborations with a total potential value of 277 billion USD, as traditional pharmaceutical companies act as "super buyers" acquiring AI platform pipelines. Second, ByteDance's AI drug discovery business unit has launched a spin-off for independent financing, showing that big internet players are also stepping in.
Conclusion
Back to the Suzhou fund. Its investment strategy is smart: prioritize upstream general technology platforms while also covering growth-stage and mature-stage projects. Upstream tech platforms follow the "pickaxe seller" logic—regardless of which pharma company's pipeline succeeds, upstream tools are essential. Growth and mature-stage projects already have data and pipeline validation, offering higher certainty. This is a combination move that covers early-stage high risk while locking in mid-to-late stage certainty.
This 5 billion is just the beginning. As local parent funds, central SOE strategic emerging industry funds, and industrial capital all flood into AI-driven drug discovery, the real question is no longer "whether to invest in AI pharma," but "who will identify the winner that delivers Phase III data in this consolidation."
The answer will become clear in two to three years.